Please select the option that best describes you:
Topics:
Rheumatology • ANCA Vasculitis • Allergy & Immunology • Pulmonology • EGPA • Eosinophilic granulomatosis with polyangiitis • Journal Club ft. NEJM publications • Diffuse Parenchymal Lung Disease • General Pulmonary • Obstructive Lung Disease • Eosinophilic Disorders
Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?
Does the severity of asthma play a role in decision making?
Answer from: at Community Practice
Not specifically. Both of these medications are effective in controlling severe asthma and allow for OCS reduction in EGPA patients, though benra did demonstrate more serum eosinophil depletion. The MANDARA trial demonstrated non-inferiority so both of these medications and MOAs are effective. Patie...
Sign in or Register to read more